IP Library Granted Patent US 11,779,610
Granted Patent B2
US 11,779,610 · App. 17/536,841 · Granted Oct 10, 2023

Acellular soft tissue-derived matrices and methods for using same

Inventors: Yen-Chen Huang (East Brunswick, NJ); Asia Ivery (Hammond Plains, CA); Bryan Choi (San Marcos, CA); Benjamin Schilling (Pittsburgh, PA); Manh-Dan Ngo (Matawan, NJ)
Assignee: Musculoskeletal Transplant Foundation
A61K35/35A61L27/3604A61L27/3683A61L2430/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,779,610
App. No.
17/536,841
Granted
Oct 10, 2023
Kind
B2
Abstract

Methods are provided for treatment of several conditions of one or more body features, where the method comprises implanting an acellular soft tissue-derived matrix in, on, proximate to, or a combination thereof, the body feature, wherein the acellular soft tissue-derived matrix comprises a delipidated, decellularized adipose matrix. The delipidated, decellularized adipose tissue matrix is produced by delipidating an adipose tissue sample, followed by decellularizing the delipidated adipose tissue sample. The resulting matrix contains a proportion of lipids which is less than the proportion of lipids contained in a matrix produced by decellularizing an adipose tissue sample prior to delipidating. The delipidated, decellularized adipose matrix may be provided as particles, a slurry, a paste, a gel, an injectable form, or in some other form.

Claims (39)

1. A method for treatment of a condition of a body feature, the method comprising implanting an acellular soft tissue-derived matrix in, on, proximate to, or a combination thereof, the body feature, wherein the acellular soft tissue-derived matrix comprises a delipidated, decellularized adipose tissue matrix derived from a first sample of adipose tissue which has been delipidated prior to decellularizing, wherein the delipidated, decellularized adipose tissue matrix contains a first proportion of lipids which is less than a second proportion of lipids contained in a processed adipose tissue derived from a second sample of adipose tissue which has been decellularized prior to delipidating.

2. The method of claim 1 , wherein the treatment comprises one or more of:

volume restoration or replacement,

volume augmentation,

increasing, enhancing, or improving volume retention,

deficit management,

cushioning or padding areas where tissue is missing or has been removed;

healing, repair or reconstruction of a wound,

providing a stimulus to host tissue,

reconstructing or reshaping at least a portion of a body feature,

reduction or elimination of undesirable defects or attributes, and

restoration of damaged or atrophied tissue.

3. The method of claim 2 , wherein the treatment is selected from: filling, cushioning, padding, reshaping, or augmenting a facial defect or attribute, rejuvenating a facial defect or attribute, and repairing or regenerating tissue of a facial defect or attribute.

4. The method of claim 3 , wherein the treatment is selected from: rejuvenation of facial skin, a lip, an eyelid, a cheek, a chin, or a temple; reshaping or recontouring a lip, a check, a temple, a jawline, or a temple; reducing or eliminating wrinkles, nasolabial folds, a dimple, a dip, a divot, a scar, or a combination thereof; augmentation of a lip, a cheek, a chin, or a temple; craniofacial repair or reconstruction.

5. The method of claim 2 , wherein the treatment is selected from: face volumization, hand volumization, fat pad volumization, temple volumization, breast volumization, and volumization of an atrophied, diseased, or cosmetically undesirable body feature.

6. The method of claim 2 , wherein the treatment is breast reconstruction, breast reshaping, breast augmentation, or a combination thereof.

7. The method of claim 1 , wherein the condition comprises one or more of:

atrophy,

diseased tissue,

a congenital defect,

weak or strained body feature,

a tunneling wound,

a chronic or acute wound,

a void, cavity, space, or pocket in a tissue or body feature resulting from disease, trauma or a therapeutic treatment,

lipoatrophy,

age-related defects or attributes,

and aesthetically undesirable attributes.

8. The method of claim 7 , wherein the condition is one or more of: fat pad atrophy; temple atrophy, cheek atrophy, a void, pocket or other defect in a breast created during a surgical procedure, cleft lip, cleft palate, cleft chin, HIV lipoatrophy, radiation fibrosis syndrome, a superficial burn, wrinkles, a dimple, a dip, a divet, drooping eyelid, nasolabial folds, jowls, insufficiently cushioned bony prominence, asymmetry, weakened or strained vocal chords, and other undesirable attributes.

9. The method of claim 1 , wherein the body feature is one or more of: a face or portion thereof, a craniofacial feature, an extremity, a joint, a buttock, a torso or portion thereof, a back or portion thereof, dermis, muscle, and nerve.

10. The method of claim 9 , wherein the body feature is one or more of: a mouth, a forehead, a cheek, a chin, pre-jowls, a temple, an eyelid, a nose, an arm, a shoulder, a wrist, a hand, a finger, a chest, a breast, an abdomen, a leg, a hip, a knee, a calf, a shin, a foot, a toe, a joint, a fat pad, dermis, a muscle, a nerve, a blood vessel, a bone, a tendon, a ligament, a heart, and a lung.

11. The method of claim 1 , wherein the delipidated, decellularized adipose tissue matrix has a particulate form, an injectable form, or a combination thereof.

12. The method of claim 1 , wherein the delipidated, decellularized adipose tissue matrix is dehydrated, partially dehydrated, or not dehydrated.

13. The method of claim 1 , wherein the delipidated, decellularized adipose tissue matrix is a component of an implant and the method comprises implanting the implant.

14. The method of claim 13 , wherein the implant is a particulate form, an injectable form, or a combination thereof.

15. The method of claim 13 , wherein the implant is dehydrated, partially dehydrated, or not dehydrated.

16. The method of claim 13 , wherein the implant further comprises a carrier.

17. The method of claim 13 , wherein the implant is a slurry, paste or gel.

18. The method of claim 13 , wherein the implant further comprises tissuegenic cells exogenous to the first sample of adipose tissue, growth factors exogenous to the first sample of adipose tissue, or a combination thereof.

19. The method of claim 1 , wherein the treatment comprises at least one of a cosmetic surgical procedure and a reconstructive surgical procedure.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2025
From: HUANG, YEN-CHEN; IVERY, ASIA; CHOI, BRYAN; SCHILLING, BENJAMIN; NGO, MANH-DAN
To: MUSCULOSKELETAL TRANSPLANT FOUNDATION
Reel/Frame 072097/0352 →
SECURITY INTEREST Recorded Jul 27, 2023
From: MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC.
To: M&T BANK
Reel/Frame 064401/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2023
From: HUANG, YEN-CHEN; IVERY, ASIA; CHOI, BRYAN; SCHILLING, BENJAMIN; NGO, MANH-DAN
To: MUSCULOSKELETAL TRANSPLANT FOUNDATION
Reel/Frame 062603/0610 →